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Background-—Comparing heart failure (HF) outcomes across hospitals requires adequate risk adjustment. We aimed to develop
and validate a model that can be used to compare quality of HF care across hospitals.
Methods and Results-—We included patients with HF aged ≥18 years admitted to one of 433 hospitals that participated in the
Premier Inc Data Warehouse. This model (Premier) contained patient demographics, comorbidities, and acute conditions present
on admission, derived from administrative and billing records. In a separate data set derived from electronic health records, we
validated the Premier model by comparing hospital risk-standardized mortality rates calculated with the Premier model to those
calculated with a validated clinical model containing laboratory data (LAPS [Laboratory-Based Acute Physiology Score]). Among the
200 832 admissions in the Premier Inc Data Warehouse, inpatient mortality was 4.0%. The model showed acceptable
discrimination in the warehouse data (C statistic 0.75; 95% confidence interval, 0.74–0.76). In the validation data set, both the
Premier model and the LAPS models showed acceptable discrimination (C statistic: Premier: 0.76 [95% confidence interval, 0.74–
0.77]; LAPS: 0.78 [95% confidence interval, 0.76–0.80]). Risk-standardized mortality rates for both models ranged from 2% to 7%. A
linear regression equation describing the association between Premier- and LAPS-specific mortality rates revealed a regression line
with a slope of 0.71 (SE: 0.07). The correlation coefficient of the standardized mortality rates from the 2 models was 0.82.
Conclusions-—Compared with a validated model derived from clinical data, an HF mortality model derived from administrative data
showed highly correlated risk-standardized mortality rate estimates, suggesting it could be used to identify high- and low-
performing hospitals for HF care. ( J Am Heart Assoc. 2018;7:e005256. DOI: 10.1161/JAHA.116.005256.)
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H eart failure (HF) accounts for 1 million hospitaladmissions and $39 billion spent per year.1,2 This large
volume and high cost has led inpatient HF care to become a
major focus of hospital quality measurement and improve-
ment efforts, including public reporting of hospital-level
mortality and readmission rates on websites such as Hospital
Compare.3
To ensure that observed differences in outcomes between
hospitals are not largely the result of differences in patient
characteristics, care must be taken to adjust for case mix
when describing differences in quality across hospitals.
When estimating risk-standardized outcomes, analyses
should also take into account hospital size and the clustered
nature of the data (patients within hospitals) and should
include only variables that are not related to the quality of
care delivered.4 Finally, the risk-adjustment model should be
validated in different populations of patients and across
hospitals. Although electronic health record (EHR) data are
likely to become the data used for these purposes in the
future, EHR data are not routinely available, meaning that
there is still a need for risk-adjustment methods that do not
use clinical data. The aim of this study was to develop and
validate a model that can be used to compare quality of HF
care across hospitals in situations in which clinical data are
not available.
A recent innovation that will facilitate severity adjustment
in claims data is the development of multihospital databases
(eg, Premier, University HealthSystem Consortium) that
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standardize highly detailed billing data across hospitals,
providing time- or date-stamped information about all tests
and services provided to individual patients.5–9 Using one of
these data sets, we sought to develop and validate a model
that could be used to compare hospitals’ performance in the
care of HF patients. Then, in a separate hospital data set
derived from hospital EHRs, we aimed to validate this model
at the hospital level by comparing hospital risk-standardized
mortality rates (RSMRs) for our model with RSMRs calculated
from a validated model that uses laboratory results to predict
mortality.
Methods
Derivation and Internal Validation Cohort
We gathered data from the cost-accounting systems of 433
hospitals that participated in the Premier Inc Data Ware-
house (PDW; a voluntary, fee-supported database) between
January 1, 2009, and June 30, 2011. PDW contains all
elements found in hospital claims derived from the Uniform
Billing 04 form. In addition, PDW contains an itemized, date-
stamped log of all items and services charged to the
patient or the insurer, including medications, diagnostic and
therapeutic services, and laboratory tests. PDW includes
15% to 20% of all US hospitalizations. Participating
hospitals are drawn from all regions of the United States,
with greater representation from urban and southern
hospitals. PDW has been used extensively for research
purposes.5–9 Because the data are proprietary, we are not
able to make the data set or study materials available to
other researchers.
We included patients who were aged ≥18 years and had a
principal International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) diagnosis of HF or a
principal diagnosis of respiratory failure with secondary
diagnosis of HF when both HF and respiratory failure were
coded “present on admission” (POA; ICD-9-CM codes for HF:
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91, 404.93, 428.xx10,11; for respiratory failure: 518.81,
518.82, 518.84). Given the broad set of inclusion codes, we
ensured that patients were treated for acute decompensated
HF during the hospitalization by restricting the cohort to
patients in whom at least 1 HF therapy (including diuretics,
metolazone, inotropes, vasodilators, or intra-aortic balloon
pump) was initiated within the first 2 days of hospitalization.
In administrative data sets, the duration of the first hospital
day includes partial days that can vary in length, so we chose
the first 2 days of hospitalization (rather than just the first
day) for initiation of an HF therapy. We excluded patients with
a pediatric or psychiatric attending physician, those with
elective admissions, and those who were transferred from or
to another acute care facility (because we could not
accurately determine the onset or subsequent course of their
illness). For patients with repeat visits at a single hospital, 1
visit was randomly selected for inclusion. Patients were
randomly assigned to a derivation cohort (80%) and an
internal validation cohort (20%). The institutional review board
at Baystate Medical Center granted permission to conduct the
study and granted a waiver of informed consent because of
the deidentified nature of the data.
External Validation Cohort
We validated the model in a population of patients with HF
seen at hospitals that contributed to the HealthFacts
database (Cerner Corp.) between January 2010 and December
2012. HealthFacts is a multihospital data set derived from the
comprehensive EHRs of 116 geographically and structurally
diverse hospitals throughout the United States. HealthFacts
contains time-stamped pharmacy, laboratory, and billing
information and contains records, including clinical data such
as laboratory data, of >84 million acute admissions, emer-
gency room visits, and ambulatory visits. We limited the
sample to hospitals that contributed to the pharmacy,
laboratory, and diagnosis segments of the database and had
at least 20 eligible HF patients during the study period (to
obtain stable hospital rates) after applying the same patient-
level inclusion criteria.
Outcome
The primary outcome for both cohorts was hospital-specific
risk-standardized all-cause in-hospital mortality.
Clinical Perspective
What Is New?
• In a data set derived from electronic health records, we
compared 2 models that calculate hospital mortality rates
for patients with heart failure and found that a model that
used only billing data performed very similarly to a model
that used clinical data derived from medical records.
What Are the Clinical Implications?
• When using data sets that contain only information from
hospitalizations (ie, those that lack prior outpatient data)
or when clinical data are not available, our model that
uses billing data could be useful for comparing quality of
heart failure care across hospitals; it also allows for
identification of hospitals with low mortality rates, creat-
ing an opportunity to conduct future studies that examine
strategies of high-performing hospitals for heart failure
care.
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Model Derivation
Patient predictors of mortality
Using the derivation cohort, we identified candidate variables
that were used in prior risk adjustmentmodels,10,12,13 including
patient age, sex, marital status, insurance status, and race/
ethnicity. We used software provided by the Healthcare Costs
and Utilization Project of the Agency for Healthcare Research
and Quality14,15 to identify the presence of comorbid condi-
tions. In addition, we used POA codes to identify other acute
conditions that are of concern in the setting of HF but that are
not recognized in the Elixhauser comorbidity index. These
conditions included atrial fibrillation, acute myocardial infarc-
tion, pneumonia, and acute kidney injury. Because we lacked
echocardiogram results, we used ICD-9-CM codes to identify HF
subtypes: systolic only, diastolic only, or both.
Premier model development
In the PDW population, we used a generalized estimating
equation logistic regression model, clustering on hospital, to
predict each patient’s in-hospital mortality. We initially included
all clinically relevant variables in the model, including variables
with a well-established association with mortality (eg, age), all
conditions included in the Elixhauser comorbidity index,14 and
selected comorbid acute illnesses (eg, acute myocardial
infarction that was present on admission). Using backward
selection, we retained variables in the final model (hereafter
called the “Premier” model) with P<0.05. We calculated the
area under the receiver operating characteristic curve (C
statistic) and examined the model’s calibration. We then
applied the model coefficients to the validation cohort and
examined model fit. Of note, we previously externally validated,
at the patient level, the Premier model by comparing its
performance to the performance of other published clinical HF
models in a separate clinical data set.16
Laboratory-Based Acute Physiology Score model
development
The Laboratory-Based Acute Physiology Score (LAPS) is a
validated score that uses laboratory data derived from an EHR
to predict in-hospital mortality across conditions, including
HF. LAPS uses a 2-stage algorithm. First, selected variables
are used to stratify patients into low and high mortality risk
groups. Then 14 laboratory values (anion gap; albumin; arterial
oxygen, pH, and carbon dioxide; bicarbonate; bilirubin; blood
urea nitrogen; creatinine; glucose; hematocrit; sodium; tro-
ponin I; white blood cell count) are added to the algorithm to
calculate a score.17,18 For laboratory values that are not
available, the algorithm assigns points based upon the
patient’s stage-1 mortality risk group (rather than using
imputation).17,18 Because LAPS is designed to be used as a
variable in a model that includes other patients characteristics
when predicting mortality, we developed a generalized
estimating equation logistic mortality prediction model using
the LAPS score along with age, sex, race, and comorbidities.
Using backward selection, we retained variables in the final
model with P<0.05. We also previously externally validated (at
the patient level, in a population with HF) the LAPS model by
comparing its performance to the performance of other
published clinical HF models.16
Calculation of RSMRs
For the external hospital-level validation of the Premiermodel in
the HealthFacts data set, we compared RSMRs derived using
the Premier model to those derived using the LAPS model. To
calculate RSMRs for each hospital, we fit hierarchical gener-
alized linear models using variables selected in the model-
development step. We used generalized linear mixed models
with a logit link to predict mortality and included covariates and
a random effect for hospital. We assumed that random hospital
effects are normally distributed and independent of hospital-
level covariates. This method adjusts for within-hospital
correlation of the observed outcomes. It also models the
assumption that there are underlying differences between
hospitals by allowing a random hospital intercept. For each
model, we estimated RSMRs as the ratio of predicted mortality
in each hospital given its patient mix and hospital-specific
effect, divided by expected mortality given the patient mix and
average hospital effect (ie, the mortality if the patients were
treated at the “average” hospital). Next, we used bootstrap
methods to develop a 95% confidence interval (CI) estimate of
risk-standardized mortality for each hospital. To do this, we
repeatedly sampled 55 hospitals with replacement (500
samples) from the 55 hospitals in the data set; we repeated
the hierarchical generalized linear modeling with each sample
and derived the risk-standardized mortality for each hospital,
ultimately giving us 500 RSMR estimates for each hospital.
We then used the 2.5 and 97.5 percentiles of the distribution for
each hospital as the 95% CI estimate of RSMR. To compare
RSMRs derived from the Premier and LAPS models, we first
examined the distribution of RSMRs using histograms. We then
used linear regression to model the association between the 2
rates, weighting each hospital by number of observations.11 An
intercept close to 0 and slope close to 1 would indicate similar
RSMRs by the 2 models. We also calculated correlation
coefficient between the RSMRs for Premier and LAPS, and
the median difference between model estimates.
Description of cohort definition and sensitivity analyses
To better understand the HealthFacts validation cohort
(which included both patients with a principal diagnosis of
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HF and patients with a principal diagnosis of respiratory
failure and secondary diagnosis of HF), we compared
characteristics of patients with each principal diagnosis
using v2 or Wilcoxon tests. We then conducted a sensitivity
analysis limiting our cohort to patients with a principal
diagnosis of HF and compared model fit to the results from
the full cohort. All analyses were carried out using SAS
version 9.4 (SAS Institute) and STATA version 13 (Stata-
Corp).
Results
Derivation and Internal Validation Cohort
The PDW included 433 hospitals that contributed a total of
200 832 HF patients during the study period, with between
1 and 2125 patients per hospital (Table 1). Mean patient age
was 73 years; approximately half were women (53%), and
the majority (65%) were white. The principal diagnosis was
HF in 90% of patients and respiratory failure in 10% of
patients. Approximately 71% of patients had hypertension,
41% of patients had chronic obstructive pulmonary disease,
46% had diabetes mellitus, and 40% had chronic renal
insufficiency. Patients commonly had additional POA acute
diagnoses, including acute myocardial infarction (4%), acute
kidney injury (17%), and atrial fibrillation (39%). Within the
first 2 days of hospitalization, 19% of the patients were
admitted to the intensive care unit, 5% received invasive
mechanical ventilation, 6% received noninvasive ventilation,
5% received inotropes, and 7% received intravenous vasodila-
tors. Overall, 8110 patients (4%) died in the hospital. The
80% derivation sample and the 20% internal validation
sample were statistically similar to each other and to the
larger cohort.
Validation Cohort
For external validation, we included 19 050 patients from 55
hospitals that contributed pharmacy, diagnosis, and labora-
tory data to the HealthFacts database. Compared with the
PDW, the HealthFacts cohort had a higher percentage of black
patients (28%), a slightly younger mean age (72), fewer
Medicare patients (56% versus 77% in PDW), and a similar
prevalence of comorbidities (Table 1). The rates of early
mechanical ventilation (5%), noninvasive ventilation (7%),
inotropes (6%), vasodilators (7%), and in-hospital death (4%)
were also similar.
The majority (17 391 of 19 050, or 91.3%) of the included
patients had a principal diagnosis of HF, whereas the
remaining 1659 had a principal diagnosis of respiratory
failure with a secondary diagnosis of HF (Table 2). Nearly all
(18 737 of 19 050, or 98.3%) patients included in the
HealthFacts cohort received diuretics during their first 2 days
of hospitalization. Among patients with a principal diagnosis
of HF, 98.8% received diuretics within the first 2 days of
hospitalization, and the remainder received ≥1 of the other HF
therapies. Among patients with a principal diagnosis of
respiratory failure, 93% received diuretics within the first
48 hours, and the remaining 7% received ≥1 of the other
therapies (inotropes, vasodilators, or intra-aortic balloon
pump).
There were further differences between patients with a
principal diagnosis of HF and a principal diagnosis of
respiratory failure. Patients with a principal diagnosis of
respiratory failure and secondary diagnosis of HF were slightly
younger than patients with a principal diagnosis of HF and
were more likely to be white (versus other races), to have
comorbid illnesses, or to have acute conditions (Table 2). The
respiratory failure group also had a much higher mortality rate
(13% versus 3%) than the group with a principal diagnosis of
HF.
Model Performance
The Premier model showed acceptable calibration across
deciles of predicted mortality ranging from 0.9% to 14.9%
with C statistics of 0.75 (95% CI, 0.74–0.76) in the PDW
cohort and 0.76 in the validation cohort (95% CI, 0.74–0.77).
For further details, please see the prior publication16; for the
model coefficients, see Table 3.
LAPS also showed good calibration in the validation cohort
across deciles of predicted mortality ranging from 0.7% to
16.0% with a C statistic of 0.78 (95% CI, 0.76–0.80; for the
model coefficients, see Table 4).
Premier Versus LAPS: Profiling Hospitals
RSMRs in the HealthFacts data had distributions that varied
slightly by model. For both Premier and LAPS, distributions
of hospital-level RSMRs ranged from 2% to 7% (Figure 1). The
slope of the weighted regression line of the Premier- versus
LAPS-specific mortality rates was 0.71 (SE: 0.07). The
Pearson correlation coefficient of the standardized mortality
rates from the 2 models was 0.82 (P<0.001; Figure 2). The
median difference between RSMRs estimated from the
models was 0.0001.
Sensitivity Analyses
We conducted a sensitivity analysis in which we applied the
model developed in the Premier data set to a HealthFacts
cohort limited to patients with a principal diagnosis of HF
to determine if our inclusion of patients with a princi-
pal diagnosis of respiratory failure and secondary diagnosis
DOI: 10.1161/JAHA.116.005256 Journal of the American Heart Association 4
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Table 1. Patient and Hospital Characteristics in Premier and HealthFacts
Premier Data
HealthFacts
Data P Value
Total patients, N 200 832 19 050
Number of hospitals 433 55
Demographics
Age, mean (median, Q1–Q3) 73.4 (76, 65–85) 72.0 (75, 62–84) <0.0001
Female 105 413 (52.5) 9892 (51.9) 0.1380
Race/ethnicity <0.0001
White 130 634 (65.0) 12 585 (66.1)
Black 34 165 (17.0) 5304 (27.8)
Hispanic 9442 (4.7) 341 (1.8)
Other 26 591 (13.2) 820 (4.3)
Insurance <0.0001
Medicare 154 219 (76.8) 10 606 (55.7)
Medicaid 13 133 (6.5) 1063 (5.6)
Private 22 343 (11.1) 1906 (10.0)
Uninsured 7257 (3.6) 629 (3.3)
Other/unknown 3880 (1.9) 4846 (25.4)
Clinical characteristics
Comorbidities
Valvular disease 4069 (2.0) 562 (3.0) <0.0001
Pulmonary circulation disease 5423 (2.7) 559 (2.9) 0.0577
Peripheral vascular disease 26 472 (13.2) 1849 (9.7) <0.0001
Hypertension 142 658 (71.0) 11 468 (60.2) <0.0001
Paralysis 4010 (2.0) 322 (1.7) 0.0036
Other neurological disorders 16 712 (8.3) 1253 (6.6) <0.0001
Chronic pulmonary disease 82 606 (41.1) 6588 (34.6) <0.0001
Diabetes mellitus 91 594 (45.6) 7823 (41.1) <0.0001
Hypothyroidism 36 652 (18.3) 2701 (14.2) <0.0001
Renal failure 80 713 (40.2) 6976 (36.6) <0.0001
Liver disease 5047 (2.5) 432 (2.3) 0.0379
Peptic ulcer disease, excluding bleeding 74 (0.0) 2 (0.0) 0.0615
AIDS 351 (0.2) 27 (0.1) 0.2928
Lymphoma 2012 (1.0) 161 (0.8) 0.0367
Metastatic cancer 2459 (1.2) 181 (1.0) 0.0009
Solid tumor without metastasis 3822 (1.9) 329 (1.7) 0.0879
Rheumatoid arthritis/collagen vascular disease 6193 (3.1) 511 (2.7) 0.0021
Coagulopthy 12 225 (6.1) 1061 (5.6) 0.0042
Obesity 38 337 (19.1) 3423 (18.0) 0.0002
Weight loss 10 218 (5.1) 750 (3.9) <0.0001
Fluid and electrolyte disorders 67 083 (33.4) 5547 (29.1) <0.0001
Chronic blood loss anemia 2331 (1.2) 134 (0.7) <0.0001
Deficiency anemias 67 130 (33.4) 5194 (27.3) <0.0001
Alcohol abuse 5997 (3.0) 491 (2.6) 0.0014
Drug abuse 3916 (1.9) 444 (2.3) 0.0003
Psychoses 6182 (3.1) 450 (2.4) <0.0001
Depression 21 684 (10.8) 1461 (7.7) <0.0001
Continued
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of HF affected our results. We found that the Premier
model in a cohort of patients with a principal diagnosis of
HF had a C statistic of 0.76 (95% CI, 0.75–0.76) and a
similar calibration curve to the full cohort. The C statistic
for the LAPS model was also very similar to the main
cohort (0.76; 95% CI, 0.74–0.78) and had a similar
Table 1. Continued
Premier Data
HealthFacts
Data P Value
Comorbidity score mean (median, IQR) 4.8 (5, 3–6) 4.7 (4, 3–6) <0.0001
≤2 30 966 (15.4) 4093 (21.5) <0.0001
3–4 63 576 (31.7) 6157 (32.3)
5–6 61 185 (30.5) 5451 (28.6)
≥7 45 105 (22.5) 3349 (17.6)
Acute and chronic conditions present on admission
Acute myocardial infarction 8518 (4.2) 829 (4.4) 0.4706
Acute kidney injury 34 041 (17.0) 4105 (21.5) <0.0001
Atrial fibrillation 78 434 (39.1) 6735 (35.4) <0.0001
Coronary artery disease 108 125 (53.8) 9333 (49.0) <0.0001
Pneumonia 30 097 (15.0) 2370 (12.4) <0.0001
Malnutrition 6328 (3.2) 510 (2.7) 0.0003
Ischemic heart disease 107 818 (53.7) 9224 (48.4) <0.0001
Heart failure type
Systolic 78 012 (38.8) 8668 (45.5) <0.0001
Diastolic 67 027 (33.4) 7438 (39.0) <0.0001
Treatments
Diuretics 198 244 (98.7) 18 737 (98.4) <0.0001
Noninvasive ventilation 11 611 (5.8) 1324 (7.0) <0.0001
Invasive mechanical ventilation 9969 (5.0) 939 (4.9) 0.8330
Vasopressors 3145 (1.6) 375 (2.0) <0.0001
Inotropes 9586 (4.8) 1125 (5.9) <0.0001
Vasodilators 15 024 (7.5) 1308 (6.9) 0.0020
Intra-aortic balloon pump 138 (0.1) 29 (0.2) <0.0001
Prior year HF admissions <0.0001
0 169 496 (84.4) 15 628 (82.0)
1 22 634 (11.3) 2382 (12.5)
≥2 8702 (4.3) 1040 (5.5)
Outcomes
Mortality 8110 (4.0) 800 (4.2) 0.2806
Hospital characteristics
Urban (vs rural) 178 393 (88.8) 19 028 (99.9) <0.0001
Teaching 75 626 (37.7) 15 299 (80.3) <0.0001
Geographical location <0.0001
Midwest 39 329 (19.6) 2593 (13.6)
Northeast 40 522 (20.2) 7384 (38.8)
South 87 607 (43.6) 7326 (38.5)
West 33 374 (16.6) 1747 (9.2)
Number of beds <0.0001
<199 32 998 (16.4) 2143 (11.2)
200–499 111 854 (55.7) 11 421 (60.0)
≥500 55 980 (27.9) 5486 (28.8)
Data are shown as n (%), unless otherwise noted. HF indicates heart failure; IQR, interquartile range.
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Table 2. Comparison of Patients With Principal Diagnosis of HF to Those With Principal Diagnosis of Respiratory Failure With
Secondary Diagnosis of HF
Principal Diagnosis HF
Principal Diagnosis
Respiratory Failure P Value
Total patients 17 391 (91.3) 1659 (8.7)
Demographics
Age, mean (median, Q1–Q3) 72.2 (75, 62–85) 70.4 (71, 61–81) <0.0001
Female 8922 (51.3) 970 (58.5) <0.0001
Race/ethnicity <0.0001
White 11 360 (65.3) 1225 (73.8)
Black 4952 (28.5) 352 (21.2)
Hispanic 310 (1.8) 31 (1.9)
Other 769 (4.4) 51 (3.1)
Insurance <0.0001
Medicare 9561 (55.0) 1045 (63.0)
Medicaid 953 (5.5) 110 (6.6)
Private 1750 (10.1) 156 (9.4)
Uninsured 574 (3.3) 55 (3.3)
Other/unknown 4553 (26.2) 293 (17.7)
Clinical characteristics
Comorbidities
Valvular disease 259 (1.5) 303 (18.3) <0.0001
Pulmonary circulation disease 164 (0.9) 395 (23.8) <0.0001
Peripheral vascular disease 1701 (9.8) 148 (8.9) 0.2583
Hypertension 10 356 (59.5) 1112 (67.0) <0.0001
Paralysis 273 (1.6) 49 (3.0) <0.0001
Other neurological disorders 1049 (6.0) 204 (12.3) <0.0001
Chronic pulmonary disease 5466 (31.4) 1122 (67.6) <0.0001
Diabetes mellitus 7056 (40.6) 767 (46.2) <0.0001
Hypothyroidism 2419 (13.9) 282 (17.0) <0.0001
Renal failure 6483 (37.3) 493 (29.7) <0.0001
Liver disease 403 (2.3) 29 (1.7) 0.1367
Peptic ulcer disease x bleeding 2 (0.0) 0 (0.0) 0.6622
AIDS 26 (0.1) 1 (0.1) 0.3560
Lymphoma 145 (0.8) 16 (1.0) 0.5785
Metastatic cancer 147 (0.8) 34 (2.0) <0.0001
Solid tumor without metastasis 279 (1.6) 50 (3.0) <0.0001
Rheumatoid arthritis/collagen vascular disease 457 (2.6) 54 (3.3) 0.1309
Coagulopthy 910 (5.2) 151 (9.1) <0.0001
Obesity 2944 (16.9) 479 (28.9) <0.0001
Weight loss 611 (3.5) 139 (8.4) <0.0001
Fluid and electrolyte disorders 4721 (27.1) 826 (49.8) <0.0001
Chronic blood loss anemia 125 (0.7) 9 (0.5) 0.4118
Deficiency anemias 4697 (27.0) 497 (30.0) 0.0100
Alcohol abuse 433 (2.5) 58 (3.5) 0.0135
Drug abuse 400 (2.3) 44 (2.7) 0.3637
Psychoses 369 (2.1) 81 (4.9) <0.0001
Depression 1278 (7.3) 183 (11.0) <0.0001
Continued
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calibration curve. Because limiting the cohort to a principal
diagnosis of HF excluded a large proportion of the deaths,
with more deaths excluded from some hospitals than others
(due to variation in coding of respiratory failure across
hospitals), we opted not to calculate RSMRs in this limited
cohort.
Table 2. Continued
Principal Diagnosis HF
Principal Diagnosis
Respiratory Failure P Value
Comorbidity score mean (median, IQR) 4.4 (4, 3–6) 5.1 (5, 3–6) <0.0001
≤2 3951 (22.7) 142 (8.6) <0.0001
3–4 5538 (31.8) 619 (37.3)
5–6 4937 (28.4) 514 (31.0)
≥7 2965 (17.0) 384 (23.1)
Acute and chronic conditions present on admission
Acute myocardial infarction 663 (3.8) 166 (10.0) <0.0001
Acute kidney injury 3600 (20.7) 505 (30.4) <0.0001
Atrial fibrillation 6174 (35.5) 561 (33.8) 0.1700
Coronary artery disease 8575 (49.3) 758 (45.7) 0.0049
Pneumonia 1789 (10.3) 581 (35.0) <0.0001
Malnutrition 406 (2.3) 104 (6.3) <0.0001
Ischemic heart disease 8486 (48.8) 738 (44.5) 0.0008
Heart failure type
Systolic 8218 (47.3) 450 (27.1) <0.0001
Diastolic 6867 (39.5) 571 (34.4) <0.0001
Treatments
Diuretics 17 191 (98.8) 1546 (93.2) <0.0001
Noninvasive ventilation 921 (5.3) 403 (24.3) <0.0001
Invasive mechanical ventilation 235 (1.4) 704 (42.4) <0.0001
Vasopressors 200 (1.2) 175 (10.5) <0.0001
Inotropes 907 (5.2) 218 (13.1) <0.0001
Vasodilators 1112 (6.4) 196 (11.8) <0.0001
Intra-aortic balloon pump 29 (0.2) 0 (0.0) 0.0960
Prior year HF admissions 0.7585
0 14 261 (82) 1367 (82.4)
1 2174 (12.5) 208 (12.5)
≥2 956 (5.5) 84 (5.1)
Outcomes
Mortality 577 (3.3) 223 (13.4) <0.0001
Hospital characteristics
Urban (vs rural) 17 369 (99.9) 1659 (100) 0.1472
Teaching 13 961 (80.3) 1338 (80.7) 0.7145
Geographical location <0.0001
Midwest 2369 (13.6) 224 (13.5)
Northeast 6828 (39.3) 556 (33.5)
South 6591 (37.9) 735 (44.3)
West 1603 (9.2) 144 (8.7)
Number of beds <0.0001
<199 1970 (11.3) 173 (10.4)
200–499 10 348 (59.5) 1073 (64.7)
≥500 5073 (29.2) 413 (24.9)
Data shown as n (%), unless otherwise noted. HF indicates heart failure; IQR, interquartile range.
DOI: 10.1161/JAHA.116.005256 Journal of the American Heart Association 8
Hospital Profiling in Heart Failure Lagu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Discussion
Using a mortality prediction model that showed good
performance in a multihospital billing data set composed of
inpatients with HF, we calculated hospital RSMRs in a
multihospital data set containing information from >50
hospitals’ EHRs. When we compared the Premier model’s
RSMRs with RSMR estimates derived from a clinical model
that uses laboratory data, we found that the 2 models
produced estimates of hospitals’ risk-standardized mortality
that were similar, with a correlation coefficient of 0.82. This
suggests that the Premier model could be a useful tool for
describing the quality of HF care provided by hospitals
in situations in which clinical data are not available.
Our model builds on an existing hospital-profiling model
used for hospitalized HF patients. Krumholz et al developed
and validated an administrative claims–based risk-adjustment
model for HF with the purpose of characterizing hospital
quality. This model, which is used by the Centers for Medicare
and Medicaid Services (CMS) to compare mortality rates
across hospitals for public reporting purposes, produces
results that are very similar to medical records–based
models.10,11,19,20 There are several key differences between
our model and the CMS model. First, the CMS model was
developed to predict 30-day mortality rates, whereas ours
predicts in-hospital-mortality. Second, unlike our model, the
CMS model contains all claims in the year before hospital-
ization. These claims are not available in data sets that
contain only information on hospitalizations, such as PDW.
Consequently, our model may be more broadly applicable to
Table 3. Premier Model Coefficients From Development
Sample (Premier Database), Derived Using Generalized
Estimating Equation Modeling
Covariate Estimate SE P Value
Intercept 4.1603 0.0949 <0.0001
Demographics
Age, y
<50 Ref
50–59 0.1305 0.0924 0.1579
60–69 0.2940 0.0885 0.0009
70–74 0.3784 0.0948 <0.0001
75–79 0.6849 0.0920 <0.0001
80–84 0.7570 0.0912 <0.0001
85–88 0.8364 0.0927 <0.0001
≥89 0.9584 0.0920 <0.0001
Race/ethnicity
White Ref
Black 0.2282 0.0463 <0.0001
Hispanic 0.1202 0.0740 0.1042
Other 0.0521 0.0433 0.2297
Sex
Male Ref
Female 0.1209 0.0272 <0.0001
Insurance
Medicare Ref
Private 0.1016 0.0527 0.0540
Uninsured 0.2119 0.1084 0.0507
Other/unknown 0.3766 0.0936 <0.0001
Medicaid 0.0245 0.0705 0.7284
Clinical characteristics
Comorbidities
Valvular disease 0.8410 0.0579 <0.0001
Pulmonary circulation disease 1.0029 0.0544 <0.0001
Peripheral vascular disease 0.1364 0.0361 0.0002
Hypertension 0.2556 0.0281 <0.0001
Paralysis 0.5022 0.0727 <0.0001
Other neurological disorders 0.3745 0.0395 <0.0001
Chronic pulmonary disease 0.1245 0.0269 <0.0001
Renal failure 0.1817 0.0286 <0.0001
Liver disease 0.4563 0.0708 <0.0001
Rheumatoid arthritis 0.1936 0.0693 0.0052
Coagulopathy 0.6321 0.0405 <0.0001
Drug abuse 0.2767 0.1344 0.0396
Lymphoma 0.3998 0.1051 0.0001
Solid tumor without metastasis 0.4095 0.0758 <0.0001
Continued
Table 3. Continued
Covariate Estimate SE P Value
Metastatic cancer 0.8896 0.0794 <0.0001
Acute myocardial infarction 1.2192 0.0413 <0.0001
Acute kidney injury 0.7337 0.0305 <0.0001
Atrial fibrillation 0.2415 0.0269 <0.0001
Coronary artery disease 0.5637 0.1781 0.0015
Ischemic heart disease 0.7037 0.1782 <0.0001
Pneumonia 0.6165 0.0301 <0.0001
Malnutrition 0.6160 0.0526 <0.0001
Systolic heart failure 0.2137 0.0289 <0.0001
Diastolic heart failure 0.3350 0.0298 <0.0001
Prior heart failure hospitalization
0 Ref
1 0.1394 0.0398 0.0005
>1 0.1794 0.0625 0.0041
Ref indicates referent.
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databases that contain information about hospitalizations but
lack outpatient data. The CMS model does not include
patients with a principal diagnosis of respiratory failure, and
that limits its use to patients with HF as a principal diagnosis.
The CMS model was also developed before widespread use of
POA codes, so it did not originally include POA acute
diagnoses, and POA acute diagnoses have not been added
to the CMS model in recent years. In contrast, our model
attempts to adjust for presenting severity by including some
acute diagnoses that were present at the time of admission
(eg, pneumonia or acute myocardial infarction). Finally, our
model includes all patients aged >18 years, whereas the CMS
model includes only Medicare patients, the vast majority of
whom are aged ≥65 years. Despite these differences, our C
statistics compare favorably to the CMS model, which had a C
statistic of 0.70.11
The validation of a model that can be used to profile
hospital quality of HF care has some important implications.
Because it can be used with almost any multihospital data set,
this model can be used by groups of hospitals that come
together to improve quality (“quality improvement collabora-
tives”) and will allow such collaboratives to identify hospitals
that need the most focused efforts. Perhaps more important,
our model can be used to identify high-performing hospitals
(eg, Figure 2). It is possible that hospitals with lower mortality
rates use quality-improvement and care-coordination strate-
gies to standardize the care of patients with HF that may lead
to better patient outcomes. Although we cannot use this
current data set to identify the strategies that are most likely
to improve care, future studies should consider using
qualitative methods, such as those described by Bradley
and Krumholz,21 to do so. These interviews might include
questions about hospital units that specialize in the care of HF
patients (including nurses, physicians, and managers with
expertise in HF care), use of protocols for early identification
of volume status, coordinated efforts to identify patients who
would most benefit from intensive care and procedures,
appropriate use of palliative care and hospice for patients with
end-stage disease, and interventions to integrate team
members.
This study has several strengths. First, we validated the
model for use at the hospital level in a separate population
with different demographic characteristics. Second, we pre-
viously demonstrated the patient-level performance of the
Premier model compared with published clinical HF mortality
prediction models.16 Third, our model is one of only 2 clinical
prediction models in the HF literature aimed specifically at
benchmarking hospitals and is potentially more broadly
applicable than the CMS model for the reasons stated.
Among published HF models that predict mortality in
hospitalized HF patients,22–26 most contain clinical variables,
such as systolic blood pressure and serum creatinine
level.22,23,25 In contrast, our model does not require clinical
data but performed similarly to a model that does.
Despite these strengths, this study also has several
limitations. First, our model predicts in-hospital mortality
rather than 30- or 90-day mortality because our data sets do
not contain information about postdischarge deaths. Although
inpatient mortality is widely used in outcomes research,26–28
there are concerns that hospitals with shorter length of stay
or patterns of discharging end-of-life patients to palliative care
or hospice might have lower in-hospital mortality but similar
30-day mortality.29 This is also an issue because CMS quality
metrics use 30-day rather than inpatient mortality. Second,
the lack of clinical data also introduced an additional
limitation: We could not determine HF etiology or ejection
Table 4. LAPS Model Coefficients From the HealthFacts
Cohort, Derived Using Generalized Estimating Equation
Modeling
Covariate Estimate SE P Value
Intercept 4.6381 0.2280 <0.0001
Demographics
Age, y
<50 Ref
50–59 0.1185 0.2278 0.6030
60–69 0.1010 0.2154 0.6393
70–74 0.0480 0.2296 0.8343
75–79 0.2655 0.2199 0.2272
80–84 0.3230 0.2181 0.1387
85–88 0.6662 0.2168 0.0021
≥89 0.6472 0.2149 0.0026
Race/ethnicity
White Ref
Black 0.4706 0.1200 <0.0001
Hispanic 0.4442 0.3352 0.1850
Other 0.3141 0.2036 0.1229
Comorbidities
Pulmonary circulation disease 0.5229 0.1521 0.0006
Hypertension 0.3618 0.0806 <0.0001
Paralysis 0.6055 0.2171 0.0053
Other neurological disorders 0.5606 0.1162 <0.0001
Renal failure 0.1591 0.0787 0.0433
Coagulopathy 0.8795 0.1112 <0.0001
Solid tumor without metastasis 0.5547 0.2121 0.0089
Metastatic cancer 1.2072 0.2275 <0.0001
LAPS 0.0324 0.0017 <0.0001
LAPS indicates Laboratory-Based Acute Physiology Score; Ref, referent.
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fraction, except by using diagnosis codes. Finally, our
definition of HF was based on a combination of diagnosis
and billing codes and does not include clinical data. We used a
broad set of diagnosis codes to identify patients (with both HF
and respiratory failure as principal diagnoses), but also
required the presence of at least 1 HF-specific treatment
early in the hospitalization as a proxy for clinical findings of
HF. Although many prior studies and CMS quality metrics use
diagnosis codes alone to identify patients hospitalized with
HF,10,30–32 we believe that using criteria that combine the
principal diagnosis code with early therapies is a more
specific method for identifying hospitalizations for which the
primary issue is HF.16 Furthermore, the high percentage of
patients treated with diuretics provides additional evidence
that these were hospitalizations for which the primary issue
was HF. Slightly fewer patients with a principal diagnosis of
respiratory failure received diuretics, but we feel that this is to
be expected, given that these patients are the sickest and are
most likely to suffer from low blood pressure, acute kidney
injury, and other factors that would limit the use of diuretics
but would increase the likelihood that they would receive
other HF therapies (eg, inotropes). Finally, we used this broad
set of diagnosis codes because prior work suggests that there
is variation in coding across hospitals in the use of the code
for acute respiratory failure, with some hospitals using this
code more often than others.33 If we failed to include patients
with a principal diagnosis of respiratory failure for a hospital-
level validation, the hospitals that use this code more
frequently for their sicker patients with HF might appear to
have a healthier cohort of patients with HF.
In conclusion, a mortality model designed to support
hospital profiling of inpatient mortality for patients with HF
appeared to produce similar results to a clinical model. These
data suggest that this model could be useful for comparing
quality of HF care across hospitals, especially if using data
Figure 1. Distribution of hospital RSMRs for Premier and LAPS. LAPS indicates Laboratory-Based Acute
Physiology Score; RSMR, risk-standardized mortality rate.
Figure 2. Weighted regression line comparing LAPS-derived
RSMRs with Premier-derived risk-standardized mortality. LAPS
indicates Laboratory-Based Acute Physiology Score; RSMR, risk-
standardized mortality rate.
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sets that contain only information from hospitalizations (ie,
those that lack prior outpatient data) or if clinical data are not
available. This model also allows for identification of hospitals
with low mortality rates, creating an opportunity to conduct
future studies that examine strategies of high-performing
hospitals for HF care.
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